CPT Codes Mapped to CVX Codes

This table cross-references Current Procedural Terminology (CPT™) codes that are related to vaccines, toxoids and immune globulins with their corresponding CVX codes. The goal of the table is to support mapping of CPT codes to CVX codes in systems that receive CPT codes as part of an electronic data exchange. The CVX and/or NDC code systems are highly recommended when exchanging immunization data, but if a sending system must use CPT codes, this table may be used by the receiving system to translate the CPT code to the single best CVX code equivalent. In all cases, the code utilized, be it NDC, CVX or CPT, should be the most specific and granular representation possible of the vaccine given. Where only a single vaccine exists, the CPT code is mapped to that vaccine specific CVX code. However, in many cases, a single CPT code could be used with multiple vaccines utilizing different CVX codes. In this situation, the CPT code is mapped to the “unspecified formulation” CVX code because it is not possible to infer a specific vaccine formulation from the CPT code alone.
This table is not intended to support mapping from CVX to CPT nor to be a definitive source for CPT codes. Practices must approach billing for vaccines (selection of a CPT code for a given administration) independently from recording and reporting the most specific vaccine codes to an IIS or other clinical trading partner. Active CPT codes, inactive CPT codes and pre-release CPT codes are included. Every effort is made to keep the codes current.

Sort Table by Column: Simply click on the column heading to sort the table accordingly.

The Last Updated column indicates the last time this particular CPT code was updated in this table.

CPT CODECPT DescriptionCVX CodeVaccine NameCommentsLast Updated
Date
90281 Immune globulin (Ig), human, for intramuscular use86 IG4/14/2020
90283 Immune globulin (IgIV), human, for intravenous use87 IGIV4/14/2020
90287 Botulinum antitoxin, equine, any route27 botulinum antitoxin2/28/2017
90291 Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use29 CMVIG4/14/2020
90296 Diphtheria antitoxin, equine, any route12 diphtheria antitoxin2/28/2017
90371 Hepatitis B immune globulin (HBIg), human, for intramuscular use30 HBIG4/14/2020
90375 Rabies immune globulin (RIg), human, for intramuscular and/or subcutaneous use34 RIG4/14/2020
90376 Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use34 RIG4/14/2020
90378 Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each93 RSV-MAb4/14/2020
90380 Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use306 RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 monthsCPT Code to be used for Beyfortus 0.5 mL7/21/2023
90381 Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use307 RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 monthsCPT Code to be used for Beyfortus 1.0 mL9/21/2023
90389 Tetanus immune globulin (TIg), human, for intramuscular use13 TIG4/14/2020
90393 Vaccinia immune globulin, human, for intramuscular use79 vaccinia immune globulin4/14/2020
90396 Varicella-zoster immune globulin, human, for intramuscular use36 VZIG4/14/2020
90470 H1N1 immunization administration (intramuscular, intranasal), including counseling when performed128 Novel Influenza-H1N1-09, all formulations2/28/2017
90476 Adenovirus vaccine, type 4, live, for oral use54 adenovirus, type 44/14/2020
90477 Adenovirus vaccine, type 7, live, for oral use55 adenovirus, type 74/14/2020
90581 Anthrax vaccine, for subcutaneous or intramuscular use318 Anthrax, post-exposure prophylaxis4/14/2020
90581 Anthrax vaccine, for subcutaneous or intramuscular use24 Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis4/14/2020
90585 Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use19 BCG4/14/2020
90589 Chikungunya virus vaccine, live attenuated, for intramuscular use317 Chikungunya live attenuated vaccine, 0.5 mL, PF7/19/2023
90611 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use206 Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injectionCPT Code to be used for JYNNEOS vaccine5/31/2023
90619 Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use203 meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)7/28/2020
90620 Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use163 meningococcal B, OMV4/14/2020
90621 Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use162 meningococcal B, recombinant4/14/2020
90622 Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use75 vaccinia (smallpox)CPT Code to be used for ACAM2000 vaccine5/31/2023
90623 Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use316 Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF7/19/2023
90625 Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use174 cholera, live attenuated4/14/2020
90626 Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use223 Tick-borne encephalitis, inactivated, PF, 0.25mL9/13/2021
90627 Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use224 Tick-borne encephalitis, inactivated, PF, 0.5mL9/13/2021
90630 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use166 influenza, intradermal, quadrivalent, preservative free4/14/2020
90632 Hepatitis A vaccine (HepA), adult dosage, for intramuscular use52 Hep A, adult4/14/2020
90633 Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use83 Hep A, ped/adol, 2 dose4/14/2020
90634 Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use84 Hep A, ped/adol, 3 dose4/14/2020
90636 Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use104 Hep A-Hep B4/14/2020
90644 Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use148 Meningococcal C/Y-HIB PRP4/14/2020
90645 Hemophilus influenza b vaccine (Hib), HbOC conjugate (4 dose schedule), for intramuscular use47 Hib (HbOC)2/28/2017
90646 Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, intramuscular use46 Hib (PRP-D)2/28/2017
90647 Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use49 Hib (PRP-OMP)4/14/2020
90648 Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use48 Hib (PRP-T)4/14/2020
90649 Human Papillomavirus vaccine, types 6, 11, 16, 18, quadrivalent (4vHPV), 3 dose schedule, for intramuscular use62 HPV, quadrivalent4/14/2020
90650 Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use118 HPV, bivalent4/14/2020
90651 Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use165 HPV94/14/2020
90653 Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use168 influenza, trivalent, adjuvanted4/14/2020
90654 Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use144 influenza, seasonal, intradermal, preservative free4/14/2020
90655 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use140 Influenza, seasonal, injectable, preservative free4/14/2020
90656 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use140 Influenza, seasonal, injectable, preservative free4/14/2020
90657 Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use141 Influenza, seasonal, injectable4/14/2020
90658 Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use141 Influenza, seasonal, injectable4/14/2020
90659 Influenza virus vaccine, whole virus, for intramuscular or jet injection use16 influenza, whole2/28/2017
90660 Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use111 influenza, live, intranasal4/14/2020
90661 Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use153 Influenza, injectable, MDCK, preservative free4/14/2020
90662 Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use197 influenza, high-dose, quadrivalent4/14/2020
90662 Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use135 Influenza, high dose seasonal4/14/2020
90663 Influenza virus vaccine, pandemic formulation, H1N1128 Novel Influenza-H1N1-09, all formulations2/28/2017
90664 Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal use125 Novel Influenza-H1N1-09, nasal4/14/2020
90665 Lyme disease vaccine, adult dosage, for intramuscular use66 Lyme disease2/28/2017
90666 Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use126 Novel influenza-H1N1-09, preservative-free4/14/2020
90668 Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use127 Novel influenza-H1N1-094/14/2020
90669 Pneumococcal conjugate vaccine, 7 valent, for intramuscular use100 pneumococcal conjugate PCV 72/28/2017
90670 Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use133 Pneumococcal conjugate PCV 134/14/2020
90671 Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use215 Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF9/13/2021
90672 Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use149 influenza, live, intranasal, quadrivalent4/14/2020
90673 Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use155 influenza, recombinant, injectable, preservative free4/14/2020
90674 Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use171 Influenza, injectable, MDCK, preservative free, quadrivalent4/14/2020
90675 Rabies vaccine, for intramuscular use90 rabies, unspecified formulation4/14/2020
90676 Rabies vaccine, for intradermal use40 rabies, intradermal injection4/14/2020
90677 Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use216 Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF9/13/2021
90678 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use305 RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PFCPT Code to be used for ABRYSVO1/11/2024
90679 Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use303 RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PFCPT Code to be Used for Arexvy7/19/2023
90680 Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use116 rotavirus, pentavalent4/14/2020
90681 Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use119 rotavirus, monovalent4/14/2020
90682 Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use185 influenza, recombinant, quadrivalent,injectable, preservative free4/14/2020
90685 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use161 Influenza, injectable,quadrivalent, preservative free, pediatric4/14/2020
90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use150 influenza, injectable, quadrivalent, preservative free4/14/2020
90687 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use158 influenza, injectable, quadrivalent4/14/2020
90688 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use158 influenza, injectable, quadrivalent4/14/2020
90690 Typhoid vaccine, live, oral25 typhoid, oral4/14/2020
90691 Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use101 typhoid, ViCPs4/14/2020
90692 Typhoid vaccine, heat- and phenol-inactivated (H-P), for subcutaneous or intradermal use41 typhoid, parenteral2/28/2017
90693 Typhoid vaccine, acetone-killed, dried (AKD), for subcutaneous use (U.S. military)53 typhoid, parenteral, AKD (U.S. military)2/28/2017
90694 Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use205 Influenza vaccine, quadrivalent, adjuvanted4/14/2020
90696 Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use130 DTaP-IPV4/14/2020
90697 Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use146 DTaP,IPV,Hib,HepB4/14/2020
90698 Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use120 DTaP-Hib-IPV4/14/2020
90700 Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use20 DTaP4/14/2020
90701 Diphtheria, tetanus toxoids, and whole cell pertussis vaccine (DTP), for intramuscular use01 DTP2/28/2017
90702 Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use28 DT (pediatric)4/14/2020
90703 Tetanus toxoid adsorbed, for intramuscular use35 tetanus toxoid, adsorbed2/28/2017
90704 Mumps virus vaccine, live, for subcutaneous use07 mumps2/28/2017
90705 Measles virus vaccine, live, for subcutaneous use05 measles2/28/2017
90706 Rubella virus vaccine, live, for subcutaneous use06 rubella2/28/2017
90707 Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use03 MMR4/14/2020
90708 Measles and rubella virus vaccine, live, for subcutaneous use04 M/R2/28/2017
90710 Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use94 MMRV4/14/2020
90712 Poliovirus vaccine, (any type[s]) (OPV), live, for oral use182 OPV, Unspecified2/28/2017
90713 Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use10 IPV4/14/2020
90714 Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use113 Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbedBeginning in 2005, this CPT code maps to TD preservative free. Remapped to CVX code 09 10/2021 to support active products mapped to that code.10/8/2021
90714 Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use09 Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbedBeginning in 2005, this CPT code maps to TD preservative free. Remapped to CVX code 09 10/2021 to support active products mapped to that code.10/8/2021
90715 Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use115 Tdap4/14/2020
90716 Varicella virus vaccine (VAR), live, for subcutaneous use21 varicella4/14/2020
90717 Yellow fever vaccine, live, for subcutaneous use184 Yellow fever, unspecified formulation4/14/2020
90720 Diphtheria, tetanus toxoids, and whole cell pertussis vaccine and Hemophilus influenza B vaccine (DTP-Hib), for intramuscular use22 DTP-Hib2/28/2017
90721 Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus influenza B vaccine (DTaP/Hib), for intramuscular use50 DTaP-Hib2/28/2017
90723 Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use110 DTaP-Hep B-IPV4/14/2020
90724 Influenza virus vaccine88 influenza, unspecified formulation3/3/2017
90725 Cholera vaccine for injectable use26 cholera, unspecified formulation2/28/2017
90726 Rabies vaccine90 rabies, unspecified formulation3/3/2017
90727 Plague vaccine, for intramuscular use23 plague2/28/2017
90728 BCG vaccine19 BCG3/3/2017
90730 Hepatitis A vaccine85 Hep A, unspecified formulation3/3/2017
90731 Hepatitis B vaccine45 Hep B, unspecified formulation3/3/2017
90732 Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use33 pneumococcal polysaccharide PPV234/14/2020
90733 Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use32 meningococcal MPSV44/14/2020
90734 Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use136 Meningococcal MCV4O4/14/2020
90734 Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use114 meningococcal MCV4P4/14/2020
90735 Japanese encephalitis virus vaccine, for subcutaneous use39 Japanese encephalitis SC2/28/2017
90736 Zoster (shingles) vaccine (HZV), live, for subcutaneous injection121 zoster live4/14/2020
90737 Hemophilus influenza B17 Hib, unspecified formulation3/3/2017
90738 Japanese encephalitis virus vaccine, inactivated, for intramuscular use134 Japanese Encephalitis IM4/14/2020
90739 Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use189 HepB-CpG9/16/2022
90740 Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use44 Hep B, dialysis4/14/2020
90741 Immunization, passive; immune serum globulin, human (ISG)14 IG, unspecified formulation3/3/2017
90743 Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use43 Hep B, adult4/14/2020
90744 Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use08 Hep B, adolescent or pediatric4/14/2020
90745 Hepatitis B vaccine, adolescent/high risk infant dosage, for intramuscular use42 Hep B, adolescent/high risk infant3/3/2017
90746 Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use43 Hep B, adult4/14/2020
90747 Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use43 Hep B, adultNote that the NDCs for Engerix-B are mapped to CVX 43 which is not specific to dialysis use4/14/2020
90748 Hepatitis B and Haemophilus influenzae type b vaccine (Hib-HepB), for intramuscular use51 Hib-Hep B4/14/2020
90750 Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use187 zoster recombinant6/25/2018
90756 Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use186 Influenza, injectable, MDCK, quadrivalent, preservativeEffective 1/1/20184/14/2020
90758 Zaire ebolavirus vaccine, live, for intramuscular use204 Ebola Zaire vaccine, live, recombinant, 1mL dose9/13/2021
90759 Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use220 HepB recombinant, 3-antigen, Al(OH)39/13/2021
91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use208 COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL doseCOVID-19 Vaccine - EUA authorized 12/11/20201/11/2024
91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use207 COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL doseCOVID-19 Vaccine - BLA Licensed and EUA authorized1/11/2024
91302 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use210 COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mLCOVID-19 Vaccine - EUA submission withdrawn 1/11/2024
91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use212 COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mLCOVID-19 Vaccine - EUA authorized 2/27/20211/11/2024
91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use313 COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mLOriginal and Fall 2023 COVID-19 vaccine1/11/2024
91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use211 COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mLOriginal and Fall 2023 COVID-19 vaccine1/11/2024
91305 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use217 COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucroseCOVID-19 Vaccine - EUA authorized for primary series and IC, EUA rescinded 8/31/202 for monovalent boosters 1/11/2024
91306 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use207 COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL doseCOVID-19 Vaccine - EUA authorization rescinded 8/31/2022 for adult monovalent booster dose1/11/2024
91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use218 COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucroseCOVID-19 Vaccine - EUA authorized, pediatric 5 yrs through 11 yrs dose requires dilution1/11/2024
91308 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use219 COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucroseCOVID-19 Vaccine - EUA authorized for children under 5 yrs1/11/2024
91309 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use221 COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL doseCOVID-19 Vaccine - EUA authorized for pediatric, EUA rescinded 8/31/2022 for adult monovalent booster dose1/11/2024
91310 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use225 COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mLCOVID-19 Vaccine - Potential EUA authorization booster dose1/11/2024
91311 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use228 COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL doseCOVID-19 Vaccine - EUA authorized for ages 6 mo through 5 yrs1/11/2024
91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use300 COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL doseCOVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster ages 12+ yrs1/11/2024
91313 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use229 COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL doseCOVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster for ages 18+ yrs, potential EUA ages 6 yrs through 17 yrs1/11/2024
91314 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use229 COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL doseCOVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster for ages 6 yrs through 11 yrs1/11/2024
91315 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use301 COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL doseCOVID-19 Vaccine - Potential EUA authorization bivalent booster for ages 5 yrs through 11 yrs1/11/2024
91316 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use230 COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mLCOVID-19 Vaccine - EUA authorized 12/8/2022 bivalent booster (Moderna) for ages 6 mo through 5 yrs1/11/2024
91317 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use302 COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL doseCOVID-19 Vaccine - EUA authorized 12/8/2022 bivalent vaccine (Pfizer) for ages 6 mo through 4 yrs1/11/2024
91318 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use308 COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mLFall 2023 COVID-19 vaccine 9/19/2023
91319 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use310 COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mLFall 2023 COVID-19 vaccine 9/19/2023
91320 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use309 COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mLFall 2023 COVID-19 vaccine 9/14/2023
91321 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use311 COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mLFall 2023 COVID-19 vaccine 9/14/2023
91322 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use312 COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mLFall 2023 COVID-19 vaccine 9/14/2023

 Top of Page


CPT codes are developed and maintained by the American Medical Association (AMA) and are intended to support billing for services. CPT codes have been reproduced here with permission from the AMA. CPT five-digit codes, nomenclature and other data are Copyright, American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in this cross-reference. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use.

CVX codes are codes that indicate the product used in a vaccination. They are maintained by the Centers for Disease Control and Prevention, Immunization Information System Support Branch (IISSB) for use in HL7 data transmission.

Questions regarding this table should be directed to the IIS Technical Assistance Team; CDC, National Centers for Immunization and Respiratory Diseases, Immunization Information Systems Support Branch-Informatics, 1600 Clifton Road, Mailstop E-62, Atlanta, GA 30333.


For further information on HL7 immunization data exchange and the CVX code set, contact the IIS Technical Assistance Team at:

Address:
CDC, National Centers for Immunization and Respiratory Diseases
Immunization Information System Support Branch - Informatics
1600 Clifton Road
Mailstop: E-62
Atlanta, GA 30333
Email:
iisinfo@cdc.gov (note change)

Page last reviewed: January 31, 2024